Literature DB >> 26301496

Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes.

Kaifu Chen1,2,3,4,5, Zhong Chen6,7, Dayong Wu6,7, Lili Zhang8, Xueqiu Lin1,2,9, Jianzhong Su1,2, Benjamin Rodriguez1,2, Yuanxin Xi1,2, Zheng Xia1,2, Xi Chen2, Xiaobing Shi10,11, Qianben Wang6,7, Wei Li1,2.   

Abstract

Tumor suppressors are mostly defined by inactivating mutations in tumors, yet little is known about their epigenetic features in normal cells. Through integrative analysis of 1,134 genome-wide epigenetic profiles, mutations from >8,200 tumor-normal pairs and our experimental data from clinical samples, we discovered broad peaks for trimethylation of histone H3 at lysine 4 (H3K4me3; wider than 4 kb) as the first epigenetic signature for tumor suppressors in normal cells. Broad H3K4me3 is associated with increased transcription elongation and enhancer activity, which together lead to exceptionally high gene expression, and is distinct from other broad epigenetic features, such as super-enhancers. Genes with broad H3K4me3 peaks conserved across normal cells may represent pan-cancer tumor suppressors, such as TP53 and PTEN, whereas genes with cell type-specific broad H3K4me3 peaks may represent cell identity genes and cell type-specific tumor suppressors. Furthermore, widespread shortening of broad H3K4me3 peaks in cancers is associated with repression of tumor suppressors. Thus, the broad H3K4me3 epigenetic signature provides mutation-independent information for the discovery and characterization of new tumor suppressors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26301496      PMCID: PMC4780747          DOI: 10.1038/ng.3385

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  46 in total

1.  Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing.

Authors:  Robert J Sims; Scott Millhouse; Chi-Fu Chen; Brian A Lewis; Hediye Erdjument-Bromage; Paul Tempst; James L Manley; Danny Reinberg
Journal:  Mol Cell       Date:  2007-11-30       Impact factor: 17.970

Review 2.  The role of the Ikaros gene in lymphocyte development and homeostasis.

Authors:  K Georgopoulos; S Winandy; N Avitahl
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

3.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

4.  Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.

Authors:  C Virely; S Moulin; C Cobaleda; C Lasgi; A Alberdi; J Soulier; F Sigaux; S Chan; P Kastner; J Ghysdael
Journal:  Leukemia       Date:  2010-04-15       Impact factor: 11.528

5.  Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.

Authors:  Zhong Chen; Xun Lan; Jennifer M Thomas-Ahner; Dayong Wu; Xiangtao Liu; Zhenqing Ye; Liguo Wang; Benjamin Sunkel; Cassandra Grenade; Junsheng Chen; Debra L Zynger; Pearlly S Yan; Jiaoti Huang; Kenneth P Nephew; Tim H-M Huang; Shili Lin; Steven K Clinton; Wei Li; Victor X Jin; Qianben Wang
Journal:  EMBO J       Date:  2014-12-22       Impact factor: 11.598

6.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

7.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

8.  UpSET recruits HDAC complexes and restricts chromatin accessibility and acetylation at promoter regions.

Authors:  Hector Rincon-Arano; Jessica Halow; Jeffrey J Delrow; Susan M Parkhurst; Mark Groudine
Journal:  Cell       Date:  2012-11-21       Impact factor: 41.582

9.  Genome-wide dynamics of Pol II elongation and its interplay with promoter proximal pausing, chromatin, and exons.

Authors:  Iris Jonkers; Hojoong Kwak; John T Lis
Journal:  Elife       Date:  2014-04-29       Impact factor: 8.140

10.  Rate of elongation by RNA polymerase II is associated with specific gene features and epigenetic modifications.

Authors:  Artur Veloso; Killeen S Kirkconnell; Brian Magnuson; Benjamin Biewen; Michelle T Paulsen; Thomas E Wilson; Mats Ljungman
Journal:  Genome Res       Date:  2014-04-08       Impact factor: 9.043

View more
  125 in total

1.  Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex.

Authors:  Hongjie Shen; Wenqi Xu; Rui Guo; Bowen Rong; Lei Gu; Zhentian Wang; Chenxi He; Lijuan Zheng; Xin Hu; Zhen Hu; Zhi-Ming Shao; Pengyuan Yang; Feizhen Wu; Yujiang Geno Shi; Yang Shi; Fei Lan
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

2.  Chorioamnionitis exposure remodels the unique histone modification landscape of neonatal monocytes and alters the expression of immune pathway genes.

Authors:  Jennifer Bermick; Katherine Gallagher; Aaron denDekker; Steve Kunkel; Nicholas Lukacs; Matthew Schaller
Journal:  FEBS J       Date:  2018-12-22       Impact factor: 5.542

3.  Repression of human and mouse brain inflammaging transcriptome by broad gene-body histone hyperacetylation.

Authors:  Hao Cheng; Hongwen Xuan; Christopher D Green; Yixing Han; Na Sun; Hongjie Shen; Joseph McDermott; David A Bennett; Fei Lan; Jing-Dong J Han
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-02       Impact factor: 11.205

4.  Super-enhancers are transcriptionally more active and cell type-specific than stretch enhancers.

Authors:  Aziz Khan; Anthony Mathelier; Xuegong Zhang
Journal:  Epigenetics       Date:  2018-10-11       Impact factor: 4.528

5.  NSD1 Inactivation and SETD2 Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas.

Authors:  Xiaoping Su; Jianping Zhang; Roger Mouawad; Eva Compérat; Morgan Rouprêt; Frederick Allanic; Jérôme Parra; Marc-Olivier Bitker; Erika J Thompson; Banumathy Gowrishankar; Jane Houldsworth; John N Weinstein; Jorg Tost; Bradley M Broom; David Khayat; Jean-Philippe Spano; Nizar M Tannir; Gabriel G Malouf
Journal:  Cancer Res       Date:  2017-07-28       Impact factor: 12.701

Review 6.  The Aging Epigenome.

Authors:  Lauren N Booth; Anne Brunet
Journal:  Mol Cell       Date:  2016-06-02       Impact factor: 17.970

7.  Distinct features of H3K4me3 and H3K27me3 chromatin domains in pre-implantation embryos.

Authors:  Xiaoyu Liu; Chenfei Wang; Wenqiang Liu; Jingyi Li; Chong Li; Xiaochen Kou; Jiayu Chen; Yanhong Zhao; Haibo Gao; Hong Wang; Yong Zhang; Yawei Gao; Shaorong Gao
Journal:  Nature       Date:  2016-09-14       Impact factor: 49.962

8.  5-hydroxymethylcytosine accumulation in postmitotic neurons results in functional demethylation of expressed genes.

Authors:  Marian Mellén; Pinar Ayata; Nathaniel Heintz
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

9.  Long-range chromatin interactions in pathogenic gene expression control.

Authors:  Nahyun Kong; Inkyung Jung
Journal:  Transcription       Date:  2020-11-05

10.  SEA: a super-enhancer archive.

Authors:  Yanjun Wei; Shumei Zhang; Shipeng Shang; Bin Zhang; Song Li; Xinyu Wang; Fang Wang; Jianzhong Su; Qiong Wu; Hongbo Liu; Yan Zhang
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.